Roger Dansey has been appointed chief medical officer of Seattle Genetics (NASDAQ: [[ticker:SGEN]]). Dansey comes to Bothell, WA-based SeaGen from Merck (NYSE: [[ticker:MRK]]), where he was a senior vice president in oncology. Dansey succeeds Jonathan Drachman, who will continue working with SeaGen as a strategic advisor. SeaGen develops and sells cancer therapies based on its antibody-drug conjugate technology.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
